Search bioRxiv⌕ Search

Biology subjects

Serkova, N.

Publications and source records attributed to Serkova, N..

4 recordsLinked to original sources

An Open-Source, Excitation-Resolved UV-NIR Imaging Platform for Bioluminescence, Luminescence-Decay, and Chemical Discrimination Measurements

Multispectral imaging is a cornerstone of chemical imaging, with bioluminescence, fluorescence, and phosphorescence imaging underpin much of preclinical and analytical chemical measurements. However, conventional implementations are typically proprietary, costly, and resolve spectral content from the reflectance of a broadband source, without control over the excitation spectrum. This architecture cannot isolate excitation-dependent photophysical processes. Spectral discrimination through sequentially resolved narrowband excitation, detected on a single broadband-sensitive camera, instead enables excitation-dependent fluorescence, phosphorescence, and reflectance measurements not available to such broadband approaches. We describe AURORA-MSI, an open-source multispectral platform that inverts this arrangement with fourteen narrowband LEDs spanning 367-940 nm, a 120-element annular illumination ring with eight independently addressable azimuthal sectors, and a thermoelectrically cooled monochrome CMOS camera. Radiometric calibration, spatial uniformity mapping, and camera noise characterization establish the quantitative measurement foundation. In bioluminescence imaging, AURORA-MSI localized sources in a calibrated tissue-mimicking mouse phantom comparably to a commercial Revvity IVIS Spectrum, detected luciferase-expressing HSJD-GBM1-001 glioblastoma cells across a dilution series, with reduced replicate consistency at the lowest densities, and mapped substrate-free fungal-pathway emission in an intact bioluminescent Petunia hybrida, none requiring photon-counting instrumentation. Time-resolved phosphorescence decay imaging of six inorganic phosphors over 33 minutes found tri-exponential models adequate at early times, while distributed-lifetime models were preferred at extended timescales. Multispectral image-texture features extracted across all fourteen excitation bands discriminated ten pharmaceutical and household powders spanning distinct chemical compositions and, in two cases, distinct formulations of the same compound. Generality beyond these regimes was established through dual-excitation fluorescence fingerprinting of fifteen mineral specimens and wavelength-selective plant-tissue imaging exploiting UV and NIR penetration-depth differences. Excitation-side spectral encoding enables photophysical measurements that detection-side systems with uncontrolled broadband illumination cannot isolate, and the cooled-camera architecture supports weak-signal modalities without photon-counting instrumentation.

biophysics↗

MRI-Guided Focused Ultrasound Blood-Brain Barrier Opening Increases Drug Delivery and Efficacy in a Diffuse Midline Glioma Mouse Model

Diffuse intrinsic pontine glioma (DIPG) is the most common and deadliest pediatric brainstem tumor and is difficult to treat with chemotherapy in part due to the blood-brain barrier (BBB). Focused ultrasound (FUS) and microbubbles (MBs) have been shown to cause BBB disruption (BBBD), allowing larger chemotherapeutics to enter the parenchyma. Panobinostat is an example of a promising in vitro agent in DIPG with poor clinical efficacy due to low BBB penetrance. In this study, we hypothesized that using FUS to disrupt the BBB allows higher concentrations of panobinostat to accumulate in the tumor, providing a therapeutic effect. Mice were orthotopically injected with a patient-derived DMG cell line, BT-245. MRI was used to guide FUS/MB (1.5 MHz, 0.615 MPa PNP, 1 Hz PRF, 10 ms PL, 3 min treatment time) / (25 {micro}L/kg, IV) targeting to the tumor location. In animals receiving panobinostat (10 mg/kg, IP) in combination with FUS/MB, a 3-fold increase in tumor panobinostat concentration was observed, with only insignificant increase of the drug in the forebrain. In mice receiving three weekly treatments, the combination of panobinostat and FUS/MB led to a 71% reduction of tumor volumes by MRI (p = 0.01). Furthermore, FUS/MB improved the mean survival from 21 to 31 days (p < 0.0001). Our study demonstrates that FUS-mediated BBBD can increase the delivery of panobinostat to an orthotopic DMG tumor, providing a strong therapeutic effect and increased survival. One Sentence SummaryFUS and microbubbles can increase the delivery of panobinostat to a patient-derived xenograft (PDX) orthotopic DMG tumor, providing a strong therapeutic effect and increased survival.

bioengineering↗

Transcriptional control of DNA repair networks by CDK7 regulates sensitivity to radiation in Myc-driven Medulloblastoma

Myc-driven Medulloblastoma remains a major therapeutic challenge due to frequent metastasis and a poor 5-year survival rate. Myc gene amplification results in transcriptional dysregulation, proliferation, and survival of malignant cells. To identify therapeutic targets in Myc-amplified medulloblastoma we performed a CRISPR-Cas9 essentiality screen targeting 1140 genes annotated as the druggable genome. CDK7 was identified as a mediator of medulloblastoma tumorigenesis. Using covalent inhibitors and genetic depletion of CDK7 we observe the cessation of tumor growth in xenograft mouse models and increase in apoptotic mechanisms. The results are attributed to repression of a core set of Myc-driven transcriptional programs mediating DNA repair. We further establish that blocking CDK7 activity sensitizes cells to ionizing radiation leading to accrual of DNA damage and extended survival and tumor latency in medulloblastoma xenograft mouse models. Our studies establish a mechanism for selective inhibition of Myc-driven MB by CDK7 inhibition combined with radiation as a viable therapeutic strategy for Myc-amplified medulloblastoma.

cancer biology↗

Super elongation complex as a targetable dependency in diffuse midline glioma

Mutations in the histone 3 gene (H3K27M) are the eponymous drivers in diffuse intrinsic pontine gliomas (DIPGs) and other diffuse midline gliomas (DMGs), aggressive pediatric brain cancers for which no curative therapy currently exists. The salient molecular consequence of these recurrent oncohistones is a global loss of repressive H3K27me3 residues and broad epigenetic dysregulation. In order to identify specific, therapeutically targetable epigenetic dependencies within this disease context, we performed an shRNA screen targeting 408 genes classified as epigenetic/chromatin-associated molecules in patient-derived DMG cultures. This approach identified AFF4, the scaffold protein of the super elongation complex (SEC), as a previously-undescribed dependency in DMG. Interrogation of SEC function demonstrated a key role for maintaining DMG cell viability and clonogenic potential while promoting self-renewal of DMG tumor stem cells. Small-molecule inhibition of the SEC with the highly-specific, clinically relevant CDK9 inhibitors atuveciclib and AZD4573 restores regulatory RNA polymerase II pausing, promotes cellular differentiation, and leads to potent anti-tumor effect both in vitro and in patient-derived xenograft models. These studies present a biologic rationale for translational exploration of CDK9 inhibition as a promising therapeutic approach in a disease which currently has no effective medical therapies.

cancer biology↗